Royal Philips has launched its groundbreaking VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe, marking a milestone in image-guided, minimally invasive heart treatment. Already adopted in the United States, VeriSight Pro offers real-time, high-res 2D and 3D imaging directly from inside the heart, with no need for general anesthesia.
Just 3 mm in diameter, a miniaturized ultrasound probe is embedded at the tip of a steerable catheter. As it is being navigated through the femoral vein, it enables detailed intracardiac views that support structural heart and electrophysiology interventions such as transcatheter valve repair and left atrial appendage closure.
“With VeriSight Pro 3D ICE, we now have the ability to see detailed cardiac anatomy from inside the heart in real time,” said Prof. Dr. Jörg Hausleiter of Ludwig-Maximilians-Universität Munich. “This helps streamline our workflows and makes complex procedures more accessible to patients who may not tolerate more invasive imaging approaches.”
Unlike conventional methods similar to transesophageal echocardiography (TEE), often demanding general anesthesia and extended operating room time, VeriSight Pro helps minimize patient stress and reduce hospital stays, potentially both improving outcomes and lowering costs.
“VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience,” said Stacy Beske, business leader of Image-Guided Therapy Devices at Philips.
VeriSight Pro is seamlessly integrated into Philips’ ecosystem, including EPIQ ultrasound systems and the Azurion image-guided therapy platform. The catheter boasts unique advanced features, such as xPlane and iRotate, empowering clinicians to see two imaging planes simultaneously and digitally guide views without having to reposition the catheter tip. These capabilities mean ultra-precise assessment and device deployment with less imaging steps. This exciting launch is a significant step towards accessible structural heart care across Europe.
